Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Andriole

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Cancer|August 16, 2012
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPaul F Pinsky, Amanda Black, Robert Grubb, et al.
The Journal of Urology|November 11, 2005
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledgeGerald Andriole, David Bostwick, Francisco Civantos, et al.
The Journal of Urology|September 17, 2004
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trialGerald Andriole, David Bostwick, Otis Brawley, et al.
Cancer|April 6, 2013
Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trialDaniel A Barocas, Robert Grubb, Amanda Black, et al.
Cancer Epidemiology|September 25, 2012
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialPaul F Pinsky, Amanda Black, Howard L Parnes, et al.
The Journal of Urology|September 17, 2004
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasiaGerald Andriole, Nicholas Bruchovsky, Leland W K Chung, et al.
Cancer|March 3, 2007
Prostate-specific antigen velocity and prostate cancer gleason grade and stagePaul F Pinsky, Gerald Andriole, E David Crawford, et al.
Cancer Causes & Control : CCC|June 20, 2006
A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States)Daniel O Koralek, Ulrike Peters, Gerald Andriole, et al.
The Journal of Urology|June 14, 2016
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United StatesSamir S Taneja, James Bennett, Jonathan Coleman, et al.
European Urology|April 2, 2013
Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasterideRoberto L Muller, Leah Gerber, Daniel M Moreira, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Cancer|August 16, 2012
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trialsPaul F Pinsky, Amanda Black, Robert Grubb, et al.
The Journal of Urology|November 11, 2005
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledgeGerald Andriole, David Bostwick, Francisco Civantos, et al.
The Journal of Urology|September 17, 2004
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trialGerald Andriole, David Bostwick, Otis Brawley, et al.
Cancer|April 6, 2013
Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trialDaniel A Barocas, Robert Grubb, Amanda Black, et al.
Cancer Epidemiology|September 25, 2012
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialPaul F Pinsky, Amanda Black, Howard L Parnes, et al.
The Journal of Urology|September 17, 2004
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasiaGerald Andriole, Nicholas Bruchovsky, Leland W K Chung, et al.
Cancer|March 3, 2007
Prostate-specific antigen velocity and prostate cancer gleason grade and stagePaul F Pinsky, Gerald Andriole, E David Crawford, et al.
Cancer Causes & Control : CCC|June 20, 2006
A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States)Daniel O Koralek, Ulrike Peters, Gerald Andriole, et al.
The Journal of Urology|June 14, 2016
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United StatesSamir S Taneja, James Bennett, Jonathan Coleman, et al.
European Urology|April 2, 2013
Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasterideRoberto L Muller, Leah Gerber, Daniel M Moreira, et al.
Pageof 6